Affinivax is advancing a next generation technology platform to enable the development of vaccines and immunotherapies. Affinivax is focused on the most challenging bacterial infections, both improving upon existing vaccines and providing vaccines for which there are no prevention strategies available today. The company’s proprietary technology platform, called MAPS™, enables the high affinity binding of protective polysaccharides and proteins in a single vaccine or immunotherapy to uniquely induce a broad and protective B and T cell immune response. The company’s lead pneumococcal vaccine candidate, ASP3772, being developed in partnership with Astellas Pharma Inc., includes 24 pneumococcal serotypes, more than any other vaccine on the market or in clinical testing today, as well as two novel conserved pneumococcal proteins. This vaccine candidate has been demonstrated to be safe and highly immunogenic in healthy adults and is currently in Phase 1/2 clinical trials.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.